Weight-loss drugs like GLP-1 agonists, including Ozempic, are in high demand due to their success in aiding weight loss, causing shortages in the US since 2022.
Pharmacies can legally create 'compounded' versions of drugs during shortages, which are custom substitutes not subject to the same FDA approval processes, allowing for easy access and affordability.
Telehealth startups have capitalized on the shortage of GLP-1 drugs like Ozempic by selling compounded versions, offering them at lower prices and without the need to wait for patents to expire.
WIRED conducted tests on ordering compounded semaglutide, the key ingredient in Ozempic, from various telehealth companies, revealing the ease and accessibility of obtaining these medications online.
Collection
[
|
...
]